Compare Equinor ASA (EQNR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Novo Nordisk A/S — how do they compare? Equinor ASA trades at $35.93 (market cap $82.75B), while Novo Nordisk A/S trades at $50.65 (market cap $222.24B). The key difference: Novo Nordisk A/S is far larger — about 2.7× Equinor ASA's market cap, and Equinor ASA pays the higher dividend (4.24%). Which is the better fit depends on your goals.
| EQNR | NVO | |
|---|---|---|
Market Cap | $82.75B | $222.24B |
Sector | Energy | Health |
52-Week High | $42.40 | $71.70 |
52-Week Low | $22.41 | $35.29 |
Enterprise Value | $94.51B | $241.20B |
Dividend Yield | 4.24% | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $35.78, down 1.13% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed recent earnings, beating expectations in Q1 2026 but missing in Q3 2025. Recent news highlights strategic investments in Norwegian Continental Shelf projects and a share buy-back program, while exiting non-core operations like Japan offshore wind.
EQNR presents a moderate investment case with a low P/E of 16.23 and strong cash flow, but faces risks from declining net income margins and volatile energy markets. Analyst sentiment is mixed with a 30% buy rating, suggesting cautious optimism amid execution and commodity price uncertainties.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
